Moderna, Inc. — Director's Dealing 2020

Mar 2, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2020-02-27

Reporting Person: Andres Juan (See remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-27	Common Stock	M	8006	$12.21	Acquired	8006	Direct
2020-02-27	Common Stock	S	2046	$34.81	Disposed	5960	Direct
2020-02-27	Common Stock	S	2188	$34.10	Disposed	3772	Direct
2020-02-27	Common Stock	S	3272	$33.05	Disposed	500	Direct
2020-02-27	Common Stock	S	500	$31.95	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-27	Stock Option (Right to Buy)	$12.21	M	8006	Disposed	2027-08-29	Common Stock (8006)	Direct
2020-02-28	Stock Option (Right to Buy)	$25.93	A	161120	Acquired	2030-02-28	Common Stock (161120)	Direct
2020-02-28	Restricted Stock Units	$0	A	28924	Acquired		Common Stock (28924)	Direct

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.63 to $35.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.62 to $34.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.60 to $33.55. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.59 to $32.54. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F6: 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.

F7: 25% of this option will vest and become exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

F8: 50% of the shares subject to this restricted stock unit award will vest on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter.